期刊文献+

柱前衍生化气相色谱法测定α-乙基-2-氧代-1-吡咯烷乙酸光学异构体 被引量:5

Pre-column derivatization GC determination for optical isomers of α-ethyl-2-O-1-pyrrolidinylacetic acid
原文传递
导出
摘要 目的:利用柱前衍生化气相色谱法,建立(S)-α-乙基-2-氧代-1-吡咯烷乙酸制备过程中产物光学纯度的检测方法,为其合成反应过程的控制提供依据。方法:以甲醇和SOCl2为衍生化试剂,采用手性色谱柱HPChiral10%Cyclodextrin(30m×0.25mm×0.25μm),载气为N2,流速1mL.min-1,进样口温度250℃,FID检测器温度250℃,程序升温,分流比15:1,进样量0.6μL。结果:α-乙基-2-氧代-1-吡咯烷乙酸浓度在0.2~4.0mg.mL-1范围内线性关系良好(r=0.999);检测限(S/N=3)为5.3μg.mL-1;定量限(S/N=10)为20.1μg.mL-1;对映体均达到基线分离。结论:该方法准确可靠,灵敏度高,重现性好,可用于(S)-α-乙基-2-氧代-1-吡咯烷乙酸合成过程的质量控制。 Objective:To establish a GC with pre-column derivatization method for determination of optical purity in synthetic (S)-α-ethyl-2-O-1-pyrrolidinylacetic acid,to set up quality control of α-ethyl-2-O-1-pyrrolidinylacetic acid in production process.Methods:Methanol and SOCl2 were used as derivatization reagents.The separation was carried out on an HP chiral 10% cyclodextrin column( 30 m×0.25 mm×0.25 μm);highly pure N2 was adopted as carrier gas at the flow rate of 1 mL·min-1;the temperature for inlet port and the FID detector were both 250 ℃;the column temperature was 120-180 ℃ and raised by program;the split ratio was 15:1;the injection amount was 0.6 μL.Result:α-ethyl-2-O-1-pyrrolidinylacetic acid has good linear relationship in the concentration range of 0.2-4.0 mg· mL-1 ( r=0.999 );the detection limit(S/N=3)was 5.3 μg·mL-1;the quantitative limit(S/N=10)was 20.1 μg·mL-1;each of optical isomers was well isolated.Conclusion:This method is accurate,reliable,sensitive and suitable for optical isomer control in the synthetic process of (S)-α-ethyl-2-O-1-pyrrolidinylacetic acid.
出处 《药物分析杂志》 CAS CSCD 北大核心 2010年第10期1891-1894,共4页 Chinese Journal of Pharmaceutical Analysis
基金 浙江省制药重中之重学科开放基金资助(20100609) 浙江省高校优秀青年教师资助计划项目(No.G0801116042610)
关键词 (S)-α-乙基-2-氧代-1-吡咯烷乙酸 左乙拉西坦 柱前衍生化 气相色谱 手性 (S)-α-ethyl-2-O-1-pyrrolidinylacetic acid levetiracetam pre-column derivatization GC chiral
  • 相关文献

参考文献12

  • 1Nina I, Michael R, Stefan S, et al. Enantioselective analysis of levetiracetam and its enantionmer R - α - ethyl - 2 - 0 - 1 - pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J Chromatogr B ,2000 ,745 :325.
  • 2Tony W, Chih - chuan C,Ta - Cheng C, et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy : An open - label mutticenter study. Epil Beha ,2009,16:468.
  • 3Francesca B, Pelayo C, Mauro C F, et al. A synthesis of levetiracetam based on (S) - N - phenylpantolaetam as a chiral auxiliary. Tetra : Asym , 2005,16 : 3739.
  • 4Barry E G, Eugene B, Christian O, et al. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepiletic drugs : A pooled analysis of data from randomized clinical trials. Epil Rese,2005,64:1.
  • 5Eric S, Philippe J, Mafia L S M, et al. Modeling and simulation of intravenous levetiracctam pharulacokinetic profiles in children to evaluate dose adaptation rules. Epil Rese, 2007,76 : 140.
  • 6Mukta D,Greg L P. Levetircetam:A review of its adjunctive use in the management of partial onset weizures. Drugs ,2000,60:871.
  • 7Petra M C C, Willem F M A, Robert T H, et al. Add - on levetiracetam in children and adolescents with refractory epilepsy: Results of an open - label multi - centre study. Offi J Euro Paedi Neur Soci, 2008,12:321.
  • 8Tiedong G, Lisa M O, Damodara R M,et al. Determination of levetiracetam in human plasma/serum/saliva by liquid chromatography - electrospray tandem mass spectrometry. Clin Chim Acia,2007,375: 115.
  • 9田国红,赵忠新.左乙拉西坦——一种具有全新作用机制的抗癫痫新药[J].中国新药与临床杂志,2006,25(10):782-786. 被引量:43
  • 10徐宝财,辛秀兰,胡燕霞,肖阳,于凉云.(S)-α-乙基-2-氧代-1-吡咯烷基乙酰胺的合成工艺进展[J].精细与专用化学品,2004,12(24):15-17. 被引量:2

二级参考文献46

  • 1田国红,赵忠新.左乙拉西坦——一种具有全新作用机制的抗癫痫新药[J].中国新药与临床杂志,2006,25(10):782-786. 被引量:43
  • 2吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 3[1]Wolfgang L, Angelika R . Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activityin a hamster model of paroxysmaldystonia [ J ]. Eur J Pharmacol, 2000,391 (3) :251 ~ 254
  • 4[2]Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles[J]. Epilepsic Disord, 2000, 2(2):99 ~ 105
  • 5[3]Shorvon S. Pyrrolidine derivatives[J]. Lancet, 2001 , 12: 1885 ~1892
  • 6[4]Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy[J]. Epilepsy, 2001, 42 (12):1611 ~ 1613
  • 7[5]Pellock J M, Glauser T A, Bebin E M, et al. Pharmacokinetic study of levetiracetam in children[ J]. Epilepsia,2001,42 ( 12 ): 1574 ~1579
  • 8[6]Kossoff E H, Bergey G K, Freeman J M. Levetiracetam psychosis in children with epilepsy [J]. Epilepsia, 2001, 42 ( 12 ): 1611 ~ 1613
  • 9[7]Pellock J M, Glauser T A, Bebin E M. Pharmacokinetic study of levetiracetam in children[J]. Epilepsia, 2001,42(12) :1574 ~ 1579
  • 10[8]Dooley M, Plosker GL. Levetiracetam: a review of its adjunctive use in the management of partial onset seizures [J]. Drugs, 2000,60(4) :871 ~893

共引文献48

同被引文献51

引证文献5

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部